SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
172.86
+0.25 (+0.14%)
At close: 4:03PM EST

173.08 +0.22 (0.13%)
After hours: 4:26PM EST

Stock chart is not supported by your current browser
Previous Close172.61
Open173.26
Bid169.60 x 900
Ask174.74 x 800
Day's Range172.26 - 174.85
52 Week Range146.80 - 179.84
Volume904,715
Avg. Volume1,409,037
Market Cap64.682B
Beta (3Y Monthly)0.61
PE Ratio (TTM)53.32
EPS (TTM)3.24
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield2.08 (1.21%)
Ex-Dividend Date2018-12-28
1y Target Est187.15
Trade prices are not sourced from all markets
  • Zacks.com featured highlights include: Allison Transmission, Cigna, Celanese and Stryker
    Zacks10 hours ago

    Zacks.com featured highlights include: Allison Transmission, Cigna, Celanese and Stryker

    Zacks.com featured highlights include: Allison Transmission, Cigna, Celanese and Stryker

  • The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo
    Zacks9 hours ago

    The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo

    The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo

  • A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
    Market Realistyesterday

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.

  • How Medtronic’s Revenues and Expenses Are Trending
    Market Realistyesterday

    How Medtronic’s Revenues and Expenses Are Trending

    Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.

  • 4 GARP Stocks for a Winning Portfolio
    Zacksyesterday

    4 GARP Stocks for a Winning Portfolio

    Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

  • Hedge Funds Are Crazy About Stryker Corporation (SYK)
    Insider Monkey5 days ago

    Hedge Funds Are Crazy About Stryker Corporation (SYK)

    The market has been volatile as the Federal Reserve continues its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points through November 16th. SEC filings and hedge fund […]

  • 7 Stocks to Buy to Survive a Bear Market
    InvestorPlace6 days ago

    7 Stocks to Buy to Survive a Bear Market

    U.S. equities have suffered from another bout of harrowing volatility this week as investors scramble to survive this bear market. The Dow Jones Industrial Average is threatening to fall below its multi-month support level to return to lows not seen since the beginning of the year. If those February lows are violated, watch for a possible reversal of much of the 2017 Trump tax cut rally.

  • Barrons.com7 days ago

    How to Ride the Short-Term Interest Rates Bonanza

    Short-term Treasuries aren’t the only place to find value. Investors can consider taking on a little more risk, analysts say.

  • GlobeNewswire9 days ago

    Stryker increases dividend 11%, declaring a $0.52 per share quarterly dividend

    Kalamazoo, Michigan, Dec. 04, 2018 -- Kalamazoo, Michigan – December 4, 2018 – Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly.

  • Why Analysts Are Mostly Positive on Boston Scientific Stock
    Market Realist15 days ago

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.

  • Moody's16 days ago

    Stryker Corporation -- Moody's assigns Baa1 rating to Stryker's Euro note offering

    Moody's Investors Service ("Moody's") today assigned a Baa1 rating to Stryker Corporation's (Stryker) proposed offering of senior unsecured Euro notes. Stryker's Baa1 ratings reflect its diversified product portfolio across its Orthopedic, MedSurg and Neurotechnology segments. Moody's expects Stryker's leverage will remain low with debt/EBITDA to remain around 2.0-2.25 times.

  • GlobeNewswire16 days ago

    Stryker announces pricing of €2.25 billion senior notes offering

    Kalamazoo, Michigan, Nov. 27, 2018 -- Stryker (NYSE:SYK) announced today that it has priced the following notes: (i) €550 million aggregate principal amount of the Company’s.

  • What Does Dentsply’s Bottom-Line Trend Indicate?
    Market Realist16 days ago

    What Does Dentsply’s Bottom-Line Trend Indicate?

    Dentsply Sirona’s (XRAY) interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter. The company’s interest income increased from $400,000 in the third quarter of 2017 to $600,000 in the third quarter. Dentsply’s net other expense increased from $900,000 in the third quarter of 2017 to $4.7 million in the third quarter. The company’s provision for income taxes decreased from $7.1 million in the third quarter of 2017 to $4.2 million in the third quarter.

  • Dentsply Stock: Analysts Remain Bullish
    Market Realist16 days ago

    Dentsply Stock: Analysts Remain Bullish

    Among the 15 analysts covering Dentsply Sirona (XRAY) in November, five analysts gave a “buy” or a higher recommendation, while ten analysts gave a “hold” recommendation. The mean rating for Dentsply stock is 2.53 with a target price of $46.73, which implies an upside potential of 28% over the closing price of $36.51 on November 23. Peers’ ratings

  • What Analysts Recommend for Hologic Stock
    Market Realist17 days ago

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.

  • A Look at Hologic’s Gross Margin Trend
    Market Realist17 days ago

    A Look at Hologic’s Gross Margin Trend

    Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.

  • Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes
    Zacks22 days ago

    Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes

    Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.

  • Analysts Remain Bullish on Stryker Stock
    Market Realist22 days ago

    Analysts Remain Bullish on Stryker Stock

    In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts gave it a “hold” rating. The mean rating for Stryker stock is 1.97 with a target price of $187.32, implying an upside potential of 11.7% over Stryker’s closing price of $167.72 on November 19, 2018.

  • What Stryker’s Bottom-Line Trend Indicates
    Market Realist22 days ago

    What Stryker’s Bottom-Line Trend Indicates

    While the company saw an income tax benefit of $37.0 million in the third quarter of 2017, in the most recent quarter, it incurred an income tax expense of $56.0 million. Stryker’s net income jumped from $434.0 million in the third quarter of 2017 to $590.0 million in the latest quarter, which translated into net earnings per share of $1.55 in the third quarter of 2018. Stryker’s net earnings per share were $1.14 in the third quarter of 2017.

  • Understanding Stryker’s Operational Performance
    Market Realist22 days ago

    Understanding Stryker’s Operational Performance

    For fiscal 2018 and 2019, Stryker’s gross margin is expected to come in at 66.29% and 66.45%, respectively, as compared with gross margins of 66.31% for fiscal 2017. In comparison, fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) are expected at 59.29%, 70.43%, and 71.91%, respectively. Stryker incurred selling, general, and administrative expenses of $1.24 billion in the third quarter of 2018 as compared with $1.10 billion in the third quarter of 2017.

  • How Stryker Is Positioned in November
    Market Realist22 days ago

    How Stryker Is Positioned in November

    Strong operational performance and upward movements in Stryker (SYK) stock have kept investors interested in the stock in 2018. In this series, we’ll explore Stryker’s financials, segment performance, analysts’ views on the stock, and valuation metrics of the company.

  • Express Scripts & Petco Tie Up, Ease Access to Pet Medicines
    Zacks22 days ago

    Express Scripts & Petco Tie Up, Ease Access to Pet Medicines

    Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.

  • Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
    Zacks22 days ago

    Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business

    Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.

  • GlobeNewswire23 days ago

    Stryker to participate in Evercore ISI HealthCONx Conference

    Kalamazoo, Michigan, Nov. 20, 2018 -- Stryker (NYSE:SYK) will participate in the Evercore ISI HealthCONx Conference on Wednesday, November 28, 2018 at the Boston Harbor Hotel.